Analyzing Cytokinetics (NASDAQ:CYTK) & Nexien Biopharma (OTCMKTS:NXEN)

Nexien Biopharma (OTCMKTS:NXEN) and Cytokinetics (NASDAQ:CYTK) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, profitability, institutional ownership, dividends and valuation.

Valuation & Earnings

This table compares Nexien Biopharma and Cytokinetics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexien Biopharma	N/A	N/A	-$240,000.00	N/A	N/A
Cytokinetics	$88.04 million	109.01	-$784.96 million	($6.84)	-11.28

Nexien Biopharma has higher earnings, but lower revenue than Cytokinetics.

Profitability

This table compares Nexien Biopharma and Cytokinetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nexien Biopharma	N/A	N/A	N/A
Cytokinetics	-784.02%	N/A	-52.86%

Analyst Ratings

This is a summary of current ratings and recommmendations for Nexien Biopharma and Cytokinetics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexien Biopharma	0	0	0	0	0.00
Cytokinetics	1	1	17	2	2.95

Cytokinetics has a consensus price target of $99.90, indicating a potential upside of 29.52%. Given Cytokinetics’ stronger consensus rating and higher possible upside, analysts plainly believe Cytokinetics is more favorable than Nexien Biopharma.

Risk & Volatility

Nexien Biopharma has a beta of -0.93, suggesting that its stock price is 193% less volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500.

Summary

Cytokinetics beats Nexien Biopharma on 6 of the 9 factors compared between the two stocks.

About Nexien Biopharma

Nexien BioPharma, Inc. focuses on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders, and medical conditions. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien BioPharma, Inc. is based in Glendale, Colorado.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.